| pubmed-article:10810459 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10810459 | lifeskim:mentions | umls-concept:C1261473 | lld:lifeskim |
| pubmed-article:10810459 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:10810459 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10810459 | lifeskim:mentions | umls-concept:C0021083 | lld:lifeskim |
| pubmed-article:10810459 | lifeskim:mentions | umls-concept:C0040715 | lld:lifeskim |
| pubmed-article:10810459 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:10810459 | lifeskim:mentions | umls-concept:C1521725 | lld:lifeskim |
| pubmed-article:10810459 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:10810459 | pubmed:issue | 373 | lld:pubmed |
| pubmed-article:10810459 | pubmed:dateCreated | 2000-6-1 | lld:pubmed |
| pubmed-article:10810459 | pubmed:abstractText | In an effort to develop more effective therapies for various sarcomas in pediatric patients, the authors have focused on using recurrent tumor-specific translocations as potential novel tumor antigens. In general, these translocations generate fusion transcription factors. Because cytotoxic T cell lymphocyte receptors recognize peptide fragments bound to major histocompatibility complex Class 1 molecules, it is possible that unique peptides spanning the translocation breakpoint region may be processed, bound to major histocompatibility complex Class I molecules and displayed on the tumor cell surface where they could be susceptible to cytotoxic T cell lymphocyte killing. The authors have investigated the PAX-3-FKHR fusion product seen in alveolar rhabdomyosarcoma, and the EWS-FLI-1 fusion product seen in Ewing's sarcoma. Peptides spanning these fusion regions contain potential major histocompatibility complex Class 1 and Class II binding motifs suggesting they may serve as novel T cell antigens. Preliminary mouse experiments suggest that cytotoxic T cell lymphocytes specific for the PAX-3-FKHR fusion peptide can be generated and can recognize and kill tumor cells bearing the PAX-3-FKHR fusion protein. Clinical trials are ongoing to determine whether this approach will be useful. | lld:pubmed |
| pubmed-article:10810459 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10810459 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10810459 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:10810459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10810459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10810459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10810459 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10810459 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:10810459 | pubmed:issn | 0009-921X | lld:pubmed |
| pubmed-article:10810459 | pubmed:author | pubmed-author:HelmanL JLJ | lld:pubmed |
| pubmed-article:10810459 | pubmed:author | pubmed-author:BerzofskyJJ | lld:pubmed |
| pubmed-article:10810459 | pubmed:author | pubmed-author:MackallCC | lld:pubmed |
| pubmed-article:10810459 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10810459 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10810459 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10810459 | pubmed:pagination | 25-31 | lld:pubmed |
| pubmed-article:10810459 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:meshHeading | pubmed-meshheading:10810459... | lld:pubmed |
| pubmed-article:10810459 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10810459 | pubmed:articleTitle | Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. | lld:pubmed |
| pubmed-article:10810459 | pubmed:affiliation | Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892-1928, USA. | lld:pubmed |
| pubmed-article:10810459 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10810459 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10810459 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10810459 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10810459 | lld:pubmed |
